How peptides work in the body

Peptides are signaling molecules

The simplest way to explain how peptides work: they send signals. Peptides bind to specific receptors on the surface of cells — or, in some cases, inside them. When a peptide binds its target receptor, it triggers a specific response.

Think of it like a lock and key. The receptor is the lock; the peptide is a key designed for that specific lock. This is called receptor specificity, and it's why peptides can be so targeted. A peptide designed to bind a growth hormone receptor won't activate one designed for thyroid hormone.

The four main ways peptides interact with the body

1. Receptor binding

The primary mechanism. Peptides circulate and bind specific receptors on cell surfaces. Once bound, they can activate (agonist), block (antagonist), or modulate (partial agonist/antagonist). For example, BPC-157 is thought to interact with receptors involved in tissue repair pathways — though researchers are still mapping the exact interactions.

2. Enzyme inhibition

Some peptides act by inhibiting specific enzymes. Enzymes are catalysts that speed up reactions; if a peptide blocks an enzyme, the reaction it controls slows or stops. This is a common mechanism in drug development and a reason peptides interest researchers studying metabolic and hormonal pathways.

3. Gene expression regulation

Some peptides influence which genes are turned on or off. This typically involves peptides that cross the cell membrane and interact with receptors inside the cell. It's of particular interest in longevity and anti-aging research, since gene expression patterns change with age.

4. Carrier protein interaction

Some peptides bind blood proteins and use them as transport vehicles. Certain peptides bind albumin, for example, which helps them circulate longer before being broken down. This matters because many peptides have short half-lives — they're degraded by enzymes in the bloodstream relatively quickly.

How peptides are processed and broken down

The body handles peptides through proteolysis — enzymes chop peptides into smaller pieces. This has three practical consequences:

• Bioavailability. Gut enzymes break down ingested peptides before absorption, so many have low oral bioavailability.
• Half-life. Peptides in the bloodstream are typically broken down within minutes to hours; some are engineered to be more stable, using carrier proteins or D-amino acids.
• Metabolites. Breakdown products may have their own activity.

Why researchers find peptides interesting

• High specificity.
• Natural compatibility — peptides already exist in the body.
• Structural diversity — the sequence determines what a peptide does.
• Tunability — sequences can be modified to increase stability or binding affinity.
• Lower toxicity potential — preliminary, and it varies by peptide and dose.

The blood-brain barrier problem

One of the biggest challenges is the blood-brain barrier (BBB) — a layer of tightly packed cells lining the brain's blood vessels that prevents most bloodstream substances from reaching the brain. Most peptides are too large to cross.

Researchers study several approaches: linking peptides to transport molecules, engineering them to be more lipophilic, direct administration (impractical), and intranasal delivery. Whether any given peptide crosses the BBB is an empirical question that requires direct evidence.

Peptide stability and half-life

Stability is resistance to breakdown by enzymes. Half-life is the time it takes for half the peptide to clear the bloodstream. Many natural peptides have very short half-lives, measured in minutes — which is a feature in the body, not a flaw.

Strategies researchers use to extend half-life include:

• PEGylation — attaching polyethylene glycol
• Amino acid substitution — swapping D- for L-amino acids
• Carrier protein attachment
• Modified delivery — depot injections

Peptides vs. small molecule drugs

The bottom line

Peptides work primarily by binding specific receptors on or inside cells, triggering targeted responses. The key mechanisms are receptor binding, enzyme inhibition, gene expression regulation, and carrier protein interaction. Challenges remain around stability, bioavailability, and crossing barriers like the BBB — but these are all active areas of research.